Latest Conference Articles

January 26th 2016, 7:56am

Gastrointestinal Cancers Symposium (ASCO GI)

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses tumor response in the CLARINET study, which examined lanreotide depot versus placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

January 26th 2016, 7:08am

Gastrointestinal Cancers Symposium (ASCO GI)

Marcovalerio Melis, MD, associate professor, Department of Surgery, NYU Langone Medical Center, discusses a study examining if surgery can be avoided in patients with advanced rectal cancer by using diffusion-weighted magnetic resonance imaging to predict pathologic response.

January 25th 2016, 3:09pm

Gastrointestinal Cancers Symposium (ASCO GI)

Patients with metastatic colorectal cancer (mCRC) had marginal yet inconsistent improvement in clinical outcomes when treated with a three-drug chemotherapy regimen plus bevacizumab compared with a doublet-bevacizumab regimen.

January 25th 2016, 11:31am

Gastrointestinal Cancers Symposium (ASCO GI)

Neoadjuvant treatment with carboplatin and paclitaxel-based chemotherapy produced a 27.9% pathologic complete response rate in patients with resectable esophageal cancer, according to results of the NEOSCOPE trial.

January 23rd 2016, 5:02pm

Gastrointestinal Cancers Symposium (ASCO GI)

The investigational anti–PD-L1 antibody avelumab demonstrated clinical activity as a second-line and maintenance therapy for patients with unresectable gastric or gastroesophageal junction cancer.

January 23rd 2016, 3:15pm

Gastrointestinal Cancers Symposium (ASCO GI)

Safi Shahda, MD, assistant professor of Clinical Medicine, Indiana University School of Medicine, discusses a phase Ib study examining the cancer stem cell pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.

January 23rd 2016, 2:40pm

Gastrointestinal Cancers Symposium (ASCO GI)

Theodore S. Hong, MD, director, Gastrointestinal Service, Department of Radiation Oncology, discusses high-dose hypofractionated proton beam therapy for unresectable primary liver cancers.

January 23rd 2016, 1:27pm

Gastrointestinal Cancers Symposium (ASCO GI)

Nearly a quarter of patients with resectable hepatocellular carcinoma experienced major tumor necrosis of greater than or equal to 50% following preoperative treatment with sorafenib.

January 22nd 2016, 3:14pm

Gastrointestinal Cancers Symposium (ASCO GI)

The PD-1 inhibitor nivolumab (Opdivo) had an overall response rate of 14% with an acceptable safety profile in patients with gastric or gastroesophageal junction cancer.

January 22nd 2016, 1:58pm

Gastrointestinal Cancers Symposium (ASCO GI)

The PD-1 inhibitor pembrolizumab (Keytruda) elicited encouraging activity with mild adverse events as a treatment for patients with advanced PD-L1–positive esophageal carcinoma.

January 22nd 2016, 1:39pm

Gastrointestinal Cancers Symposium (ASCO GI)

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the CALGB 80802 study, which examined sorafenib versus sorafenib plus doxorubicin in patients with advanced hepatocellular carcinoma in the first-line setting.

January 22nd 2016, 12:51pm

Gastrointestinal Cancers Symposium (ASCO GI)

Tanios Bekaii-Saab, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, discusses sequencing regorafenib and TAS-102 for the treatment of patients with colorectal cancer.

January 22nd 2016, 10:58am

Gastrointestinal Cancers Symposium (ASCO GI)

The immune checkpoint inhibitor nivolumab demonstrated activity in patients with previously treated esophageal cancer.

January 21st 2016, 5:27pm

Gastrointestinal Cancers Symposium (ASCO GI)

Adding liposomal irinotecan to 5-fluorouracil and leucovorin reduced the risk of death by 25% for patients with metastatic pancreatic cancer following progression on a gemcitabine-based regimen.

January 21st 2016, 2:39pm

Gastrointestinal Cancers Symposium (ASCO GI)

Holly G. Prigerson, PhD, professor of Sociology in Medicine, Irving Sherwood Wright Professor in Geriatrics, Joan and Sanford I. Weill Department of Medicine, director, Center for Research on End of Life Care, Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses chemotherapy regimens for patients with advanced gastric cancer.

January 21st 2016, 2:35pm

Gastrointestinal Cancers Symposium (ASCO GI)

Amitabh Chak, MD, professor of Medicine, Gastroenterology, Case Western Reserve University School of Medicine, discusses challenges with screening patients for Barrett's esophagus and esophageal cancer.

January 19th 2016, 4:53pm

Gastrointestinal Cancers Symposium (ASCO GI)

Preoperative treatment with short-course radiation therapy plus 3 cycles of chemotherapy improved overall survival (OS) and was associated with fewer adverse events compared with standard chemoradiation for patients with locally advanced rectal cancer.

January 19th 2016, 3:29pm

Gastrointestinal Cancers Symposium (ASCO GI)

Everolimus reduced the risk of disease progression by at least 40% in patients with either gastrointestinal neuroendocrine tumors or NETs of unknown primary origin.

January 19th 2016, 3:23pm

Gastrointestinal Cancers Symposium (ASCO GI)

For patients with advanced midgut neuroendocrine tumors, the peptide receptor radionuclide therapy Lu-Dotatate continues to confer a major therapeutic benefit, reducing the risk of disease progression or death by 79% and signaling an improvement in overall survival as well.

January 11th 2016, 1:06pm

Genitourinary Cancers Symposium (ASCO GU)

Cory Abate-Shen, PhD, research faculty, Columbia Urology, Columbia University Medical Center, discusses the challenges of bladder cancer modeling.